If you liked this article you might like

What Adam Feuerstein Got Right and Wrong About Biotech Stocks in 2016

Peregrine Pharmaceuticals (PPHM) Stock Gains on Revenue Beat

Peregrine Pharmaceuticals (PPHM) Highlighted As Weak On High Volume

Peregrine Pharmaceuticals Series E Preferred Stock Shares Cross 12% Yield Mark